Licaminlimab (OCS-02)
Dry Eye Disease (DED)
Key Facts
About Oculis
Oculis is a global biopharmaceutical company on a mission to save sight and improve eye care through visionary innovation. Founded in 2014 and publicly listed on Nasdaq, the company has built a differentiated, late-stage pipeline targeting high-prevalence diseases with significant unmet needs, including diabetic macular edema (DME), dry eye disease (DED), and optic neuritis. Its strategy leverages proprietary technology platforms like OPTIREACH® to develop non-invasive topical treatments that challenge current invasive standards of care, positioning it as a potential leader in next-generation ophthalmology therapeutics.
View full company profileAbout Oculis Holding AG
Oculis is a clinical-stage biotech on a mission to save sight and improve eye care through visionary innovation in topical drug delivery. The company has built a highly differentiated late-stage pipeline anchored by three core assets: OCS-01 for DME, Licaminlimab for dry eye disease, and Privosegtor for neuro-ophthalmic conditions like optic neuritis. Its strategy leverages proprietary technology platforms to address vast unmet medical needs in ophthalmology, transitioning key programs into Phase 3 trials following a successful U.S. IPO in 2023 which provided capital to advance its ambitious clinical agenda.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| PRP/Excipient Formulation | ECI Therapeutics | Pre-clinical |
| ALG-1007 | Allegro Ophthalmics | Pre-clinical/Phase 1 |
| SLG-100 | Selagine | Clinical Stage (Pilot trial completed) |
| Carragelose® Eyedrops | Unither Pharmaceuticals | Commercial (Out-licensing) |
| RO-7071759 | Rohto Pharmaceutical | Phase 2 |
| Urcosimod (OK-101) | OKYO Pharma | Phase 2 |